Geron Corporation’s Second U.S. Patent for Production of Pancreatic Islets from Human Embryonic Stem Cells Strengthens Company’s Intellectual Property Position

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that it has received U.S. Patent 7,326,572 with claims covering a widely used method for producing endoderm cells from human embryonic stem cells (hESCs). The production of endoderm cells is a critical step in generating pancreatic islet cells from hESCs, which Geron is developing for potential use in treating diabetes.